Merck wrapped up its recent trading day at $78.27, rising 1.46% and outpacing the sluggish S&P 500. The company’s stock has ...

Dr. Reddy's and Alvotech collaborate to develop biosimilar to Keytruda, enhancing oncology capabilities and global reach.

This was the stock's second consecutive day of gains.

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Shares of small-biotech MoonLake Immunotherapeutics MLTX rose 18% yesterday following a report issued by the Financial Times ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

Merck held talks over a potential $3 billion acquisition of MoonLake Immunotherapeutics, as it seeks to replenish its drug pipeline ...

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than ...

MoonLake’s stock rocketed 20% after reports claimed Merck made a $3 billion acquisition offer to boost its drug pipeline.

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Merck Animal Health announced the commercial availability of Armatrex silane quaternary ammonium salt, an Environmental ...